Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1214

Sort by

Sort Order Select

Journal Articles

Clinical phenotype and pathophysiological mechanisms underlying qualitative Low VWF

Blood blood.2024028035.

https://doi.org/10.1182/blood.2024028035

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Blood blood.2024027336.

https://doi.org/10.1182/blood.2024027336

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis Landscape in Frequent Blood Donors

Blood blood.2024027999.

https://doi.org/10.1182/blood.2024027999

Published: 2025

Includes: Supplemental data

Journal Articles

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Blood blood.2024025525.

https://doi.org/10.1182/blood.2024025525

Published: 2025

Includes: Supplemental data

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Prof. Uttam Kumar Nath, Karthik Kumar, Adamya Gupta, Reshma Benson, DR Arjun Kachhwaha

Blood (2023) 142 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2023-188377

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India

Debranjani Chattopadhyay, Anamika Bakliwal, Sudeep Vaniyath, Rituparna Chetia, Gaurav Dhingra, Prof. Uttam Kumar Nath

Blood (2022) 140 (Supplement 1): 11257–11258.

https://doi.org/10.1182/blood-2022-171185

Published: 2022

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

GATA3 Gene - a Potential New Biomarker Associated with Adverse Outcomes in ALK1-Negative Anaplastic Large Cell Lymphoma: Preliminary Results from a Retrospective Cohort of 80 South American Cases of Nodal Peripheral T Lymphoma

Luis Alberto de Padua Covas Lage, MD PhD, Claudio Vinicius Brito, MD, Debora Levy, MSc, PhD, Hebert Fabricio Culler, MSc, PhD, Samuel Campanelli Freitas Couto, PhD, Lucas BO Alves, PhD, Maria C Zerbini, MD PhD Prof MD, Vanderson Rocha, MD PhD, Juliana Pereira, MD PhD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-140833

Published: 2020

Journal Articles

Pre-Transplantation ST2 Levels and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Lars Klingen Gjærde, MD, Sisse Rye Ostrowski, MD PhD DMSc, Ass Prof, Niels Smedegaard Andersen, MD PhD DMSc, Lone Smidstrup Friis, MD PhD, Brian Kornblit, MD PhD, Søren Lykke Petersen, MD DMSc, Ida Schjødt, MD PhD, Henrik Sengeløv, MD DMSc, Prof

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-133876

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134088

Published: 2020

Journal Articles

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, MD, Simon Raffel, MD, Ralph Wäsch, Sebastian Scholl, Mustafa Kondakci, MD, Andreas Rank, PD Dr, Mathias Haenel, MD, Sonja Martin, MD, Katjana Schwab, MD, Julian Knaden, Klaus Wethmar, MD, Tim Sauer, MD, Wolfgang E. Berdel, Prof., MD, Georg Lenz, Martin Dugas, Monika Brüggemann, MD, Nicola Goekbuget, MD, Nael Alakel, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-136920

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-140246

Published: 2020

Journal Articles

Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD -Mutant AMLs

Suruchi Pacharne, Oliver M. Dovey, PhD, Jonathan L Cooper, Muxin Gu, Vijay Baskar, PhD, Mathias J Friedrich, Malgorzata Gozdecka, PhD, Sandeep S Rajan, PhD, Etienne De Braekeleer, PhD MSc, Maxim Barenboim, Grace Collord, Hannes Postingl, PhD, Ruben Bautista, Milena Mazan, PhD, Roland Rad, Prof., MD, Konstantinos Tzelepis, Penny Wright, George S. Vassiliou, MD PhD FRCPath, MRCP

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141743

Published: 2020

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells

Inge Van Der Werf, MSc, Phoebe Mondala, BS, Raymond Diep, BS, Larissa Balaian, PhD, Cayla Mason, BS, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, Prof. MD PhD, Jim La Clair, Peggy Wentworth, Leslie A Crews, PhD, Thomas Whisenant, PhD, Kathleen Fisch, PhD, Michael Burkart, PhD, Catriona Jamieson, MD PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-136596

Published: 2020

Journal Articles

IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML

Badder Kattih, MD, Amir Shirvani, Piroska Klement, Abel Martin Garrido, Razif Gabdoulline, Alessandro Liebich, Maximilian Brandes, Anuhar Chaturvedi, PhD, Timon Seeger, Felicitas Thol, Gudrun Gohring, Prof., MD, Brigitte Schlegelberger, MD, Robert Geffers, PhD, David John, Udo Bavendiek, Johann Bauersachs, Arnold Ganser, Joerg Heineke, Michael Heuser

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-143026

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical phenotype and pathophysiological mechanisms underlying qualitative Low VWF

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Clonal Hematopoiesis Landscape in Frequent Blood Donors

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

GATA3 Gene - a Potential New Biomarker Associated with Adverse Outcomes in ALK1-Negative Anaplastic Large Cell Lymphoma: Preliminary Results from a Retrospective Cohort of 80 South American Cases of Nodal Peripheral T Lymphoma

Pre-Transplantation ST2 Levels and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD -Mutant AMLs

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells

IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only